Skip to main content

Advertisement

SpringerLink
Log in

Higher pretherapy and significant decrease during the first 12 months of therapy in serum laminin levels may associate with hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with lamivudine

  • Original Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Laminin participates in regulating immune response in addition to being a biomarker of liver fibrosis. Lamivudine has been shown to be able to restore cytotoxic T-cell response in chronic hepatitis B. In this study, fifty-two patients with HBeAg-positive chronic hepatitis B received lamivudine treatment for more than 12 months. Serum laminin levels were determined at baseline and during treatment and analyzed regarding treatment responses at the end of 12 months of therapy. The results showed that laminin levels at 12 months of treatment in patients who lost HBeAg were significantly lower compared with baseline (P = 0.001). The baseline laminin levels were higher in HBeAg seroconversion group than those without seroconversion (P = 0.037). Compared with baseline, the levels of serum laminin in HBeAg seroconversion group showed significant decrease (P = 0.001). It is concluded that higher pretherapy and significant decrease during the first 12 months of therapy in laminin levels may associate with HBeAg seroconversion in chronic hepatitis B patients treated with lamivudine, indicating the possible novel information of laminin for clinical reference.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lai CL, Ratziu V, Yuen MF, Poynard T (2003) Viral hepatitis B. Lancet 362:2089–2094

    Article  CAS  PubMed  Google Scholar 

  2. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M (1995) A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657–1661

    Article  CAS  PubMed  Google Scholar 

  3. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI et al (1998) A 1-year trial of lamivudine for chronic hepatitis B. Asia hepatitis lamivudine study group. N Engl J Med 339:61–68

    Article  CAS  PubMed  Google Scholar 

  4. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M et al (2000) Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 31:207–210

    Article  CAS  PubMed  Google Scholar 

  5. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H et al (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521–1531

    Article  CAS  PubMed  Google Scholar 

  6. Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW et al (2007) Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 12:1295–1303

    CAS  PubMed  Google Scholar 

  7. Zoulim F, Trépo C (1998) Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol 29:151–168

    Article  CAS  PubMed  Google Scholar 

  8. Chien RN, Liaw YF, Atkins M (1999) Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 30:770–774

    Article  CAS  PubMed  Google Scholar 

  9. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B et al (2000) Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 46:562–568

    Article  CAS  PubMed  Google Scholar 

  10. Lok AS, Ghany MG, Watson G, Ayola B (1998) Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. J Viral Hepat 5:171–178

    Article  CAS  PubMed  Google Scholar 

  11. Hann HW, Jonsson Funk ML, Rosenberg DM, Davis R (2005) Factors associated with response to lamivudine: Retrospective study in a tertiary care clinic serving patients with chronic hepatitis B. J Gastroenterol Hepatol 20:433–440

    Article  CAS  PubMed  Google Scholar 

  12. Tseng TC, Liu CJ, Wang CC, Chen PJ, Lai MY, Kao JH et al (2008) A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients. Liver Int 28:1034–1041

    Article  CAS  PubMed  Google Scholar 

  13. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T et al (2007) Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81:4215–4225

    Article  CAS  PubMed  Google Scholar 

  14. Kleinman HK, Cannon FB, Laurie GW, Hassell JR, Aumailley M, Terranova VP et al (1985) Biological activities of laminin. J Cell Biochem 27:317–325

    Article  CAS  PubMed  Google Scholar 

  15. Mecham RP (1991) Receptors for laminin on mammalian cells. FASEB J 5:2538–2546

    CAS  PubMed  Google Scholar 

  16. Martinez-Hernandez A (1984) The hepatic extracellular matrix. I. Electron immunohistochemical studies in normal rat liver. Lab Invest 51:57–74

    CAS  PubMed  Google Scholar 

  17. Martinez-Hernandez A (1985) The hepatic extracellular matrix. II. Electron immunohistochemical studies in rats with CCl4-induced cirrhosis. Lab Invest 53:166–186

    CAS  PubMed  Google Scholar 

  18. Niemelä O, Risteli J, Blake JE, Risteli L, Compton KV, Orrego H (1990) Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake. Gastroenterology 98:1612–1619

    PubMed  Google Scholar 

  19. Kondo M, Miszputen SJ, Leite-mor MM, Parise ER (1995) The predictive value of serum laminin for the risk of variceal bleeding related to portal pressure levels. Hepatogastroenterology 42:542–545

    CAS  PubMed  Google Scholar 

  20. Lebensztejn DM, Sobaniec-Łotowska ME, Bauer M, Kaczmarski M, Voelker M, Schuppan D (2005) Serum fibrosis markers as predictors of an antifibrotic effect of interferon alfa in children with chronic hepatitis B. Eur J Gastroenterol Hepatol 17:843–848

    Article  CAS  PubMed  Google Scholar 

  21. Teran JC, Mullen KD, Hoofnagle JH, McCullough AJ (1994) Decrease in serum levels of markers of hepatic connective tissue turnover during and after treatment of chronic hepatitis B with interferon-alpha. Hepatology 19:849–856

    Article  CAS  PubMed  Google Scholar 

  22. Lebensztejn DM, Skiba E, Sobaniec-Lotowska ME, Kaczmarski M (2007) Serum hyaluronan and laminin level in children with chronic hepatitis B during long-term lamivudine treatment. Hepatogastroenterology 54:834–838

    CAS  PubMed  Google Scholar 

  23. Adair-Kirk TL, Atkinson JJ, Kelley DG, Arch RH, Miner JH, Senior RM (2005) A chemotactic peptide from laminin alpha 5 functions as a regulator of inflammatory immune responses via TNF alpha-mediated signaling. J Immunol 174:1621–1629

    CAS  PubMed  Google Scholar 

  24. Sato K, Katagiri K, Hattori S, Tsuji T, Irimura T, Irie S et al (1999) Laminin 5 promotes activation and apoptosis of the T cells expressing alpha3beta1 integrin. Exp Cell Res 247:451–460

    Article  CAS  PubMed  Google Scholar 

  25. Hershkoviz R, Goldkorn I, Lider O (1995) Tumour necrosis factor-alpha interacts with laminin and functions as a pro-adhesive cytokine. Immunology 85:125–130

    CAS  PubMed  Google Scholar 

  26. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C et al (2001) Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33:963–971

    Article  CAS  PubMed  Google Scholar 

  27. Liu ZW, Han QY, Zhang N, Kang W (2004) Sequential changes of serum ferritin levels and their clinical significance in lamivudine-treated patients with chronic viral hepatitis B. World J Gastroenterol 10:972–976

    CAS  PubMed  Google Scholar 

  28. Selimoglu MA, Ertekin V (2005) Is leptin a predictive factor in the end of therapy response in chronic hepatitis B? Pediatr Int 47:378–381

    Article  CAS  PubMed  Google Scholar 

  29. Gressner AM, Tittor W, Negwer A, Pick-Kober KH (1986) Serum concentrations of laminin and aminoterminal propeptide of type III procollagen in relation to the portal venous pressure of fibrotic liver diseases. Clin Chim Acta 161:249–258

    Article  CAS  PubMed  Google Scholar 

  30. Annoni G, Colombo M, Cantaluppi MC, Khlat B, Lampertico P, Rojkind M (1989) Serum type III procollagen peptide and laminin (Lam-P1) detect alcoholic hepatitis in chronic alcohol abusers. Hepatology 9:693–697

    Article  CAS  PubMed  Google Scholar 

  31. Schneider M, Voss B, Högemann B, Eberhardt G, Gerlach U (1989) Evaluation of serum laminin P1, procollagen-III peptides, and N-acetyl-beta-glucosaminidase for monitoring the activity of liver fibrosis. Hepatogastroenterology 36:506–510

    CAS  PubMed  Google Scholar 

  32. Zheng M, Cai W, Weng H, Liu R (2003) Determination of serum fibrosis indexes in patients with chronic hepatitis and its significance. Chin Med J (Engl) 116:346–349

    Google Scholar 

  33. Smedsrød B, Paulsson M, Johansson S (1989) Uptake and degradation in vivo and in vitro of laminin and nidogen by rat liver cells. Biochem J 261:37–42

    PubMed  Google Scholar 

  34. Mizushima H, Koshikawa N, Moriyama K, Takamura H, Nagashima Y, Hirahara F et al (1998) Wide distribution of laminin-5 gamma 2 chain in basement membranes of various human tissues. Horm Res 50(Suppl 2):7–14

    Article  CAS  PubMed  Google Scholar 

  35. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S et al (1998) Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 102:968–975

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest statement

The authors declare that they have no conflict of interest related to the publication of this manuscript.

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, 710061, Xi’an, Shaanxi Province, The People’s Republic of China

    Qunying Han, Sai Lou, Zhengwen Liu, Ni Zhang, Guoyu Zhang, Shaoqiong Duan & Zhu Li

  2. Department of Hepatobiliary Surgery, First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, 710061, Xi’an, Shaanxi Province, The People’s Republic of China

    Yi Lv

Authors
  1. Qunying Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sai Lou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhengwen Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ni Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guoyu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yi Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shaoqiong Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhengwen Liu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Han, Q., Lou, S., Liu, Z. et al. Higher pretherapy and significant decrease during the first 12 months of therapy in serum laminin levels may associate with hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with lamivudine. Clin Exp Med 10, 245–251 (2010). https://doi.org/10.1007/s10238-010-0091-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-010-0091-8

Keywords

Search

Navigation